[en] OBJECTIVE: To assess intraindividual biological variability of serum cartilage specific biomarker Coll2-1 and define the best standardized conditions for blood sampling. DESIGN: Blood samples were taken from 116 subjects with knee osteoarthritis (OA) at a single time point (PRODIGE study) and from 15 healthy subjects under various conditions, including fasting condition, sampling time and season, blood treatment, and type of blood collection tube (COVAR study). Type II collagen-specific biomarker Coll2-1 was directly measured in serum using an immunoassay. RESULTS: There was no significant difference on Coll2-1 values between samples collected at any of the 5 sampling times or at any of the sampling days measured. None of the sampling parameters tested had a significant impact on Coll2-1 value (clotting time, clotting temperature and temperature of blood centrifugation, type of tube). On the contrary, differences were found in between subjects and between subjects with knee OA and healthy subjects. CONCLUSION: Coll2-1 measurement is not affected by sampling specific conditions, circadian rhythm or seasons but was found elevated in subject with knee OA indicating that Coll2-1 serum variation is not linked to the study environment, but to cartilage degradation in OA. Coll2-1 assay is sufficiently robust for use in OA clinical trials.
Disciplines :
Rheumatology
Author, co-author :
Hick, Anne-Christine
Fonck, Misch
Costes, Berenice
Cobraiville, Elisabeth
Pirson, Sébastien ; Université de Liège - ULiège > Cancer-Tumours and development biology
Garcia, Laetitia
Labasse, Alain
Vander Poelen, Steven
Henrotin, Yves ; Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Language :
English
Title :
Serum Levels of Coll2-1, a Specific Biomarker of Cartilage Degradation, Are Not Affected by Sampling Conditions, Circadian Rhythm, and Seasonality.
Publication date :
2019
Journal title :
Cartilage
ISSN :
1947-6035
eISSN :
1947-6043
Publisher :
SAGE Publications, Thousand Oaks, United States - California
Kraus VB Burnett B Coindreau J Cottrell S Eyre D Gendreau M, et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011;19(5):515-42. doi:10.1016/j.joca.2010.08.019
Kraus VB Blanco FJ Englund M Henrotin Y Lohmander LS Losina E, et al. OARSI clinical trials recommendations: soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage. 2015;23(5):686-97. doi:10.1016/j.joca.2015.03.002
Mobasheri A Bay-Jensen AC Gualillo O Larkin J Levesque MC Henrotin Y. Soluble biochemical markers of osteoarthritis: are we close to using them in clinical practice? Best Pract Res Clin Rheumatol. 2017;31(5):705-20. doi:10.1016/j.berh.2018.07.002
Henrotin Y Sanchez C Cornet A Van de Put J Douette P Gharbi M. Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine. Biomarkers. 2015;20(8):540-6. doi:10.3109/1354750X.2015.1123363
Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354-62. doi:10.1038/s41584-018-0005-9
Henrotin Y Deberg M Dubuc JE Quettier E Christgau S Reginster J-Y. Type II collagen peptides for measuring cartilage degradation. Biorheology. 2004;41(3-4):543-7.
Bauer DC Hunter DJ Abramson SB Attur M Corr M Felson D, et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage. 2006;14(8):723-7. doi:10.1016/j.joca.2006.04.001
Deberg M Dubuc JE Labasse A Sanchez C Quettier E Bosseloir A, et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis. 2008;67(2):168-74. doi:10.1136/ard.2007.073452
Deberg MA Labasse AH Collette J Seidel L Reginster JY Henrotin YE. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage. 2005;13(12):1059-65. doi:10.1016/j.joca.2005.06.014
Henrotin Y Chevalier X Deberg M Balblanc JC Richette P Mulleman D, et al. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis: a research study part of the Biovisco study. J Orthop Res. 2013;31(6):901-7. doi:10.1002/jor.22297
Henrotin Y Berenbaum F Chevalier X Marty M Richette P Rannou F. Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE® CROSS) compared to placebo in painful knee osteoarthritis patients: the EPIKART study, a pilot prospective comparative randomized double blind trial. BMC Musculoskelet Disord. 2017;18(1_suppl):222. doi:10.1186/s12891-017-1585-2
Fawzy RM Hashaad NI Mansour AI. Decrease of serum biomarker of type II collagen degradation (Coll2-1) by intra-articular injection of an autologous plasma-rich-platelet in patients with unilateral primary knee osteoarthritis. Eur J Rheumatol. 2017;4(2):93-7. doi:10.5152/eurjrheum.2017.160076
Henrotin Y Gharbi M Dierckxsens Y Priem F Marty M Seidel L, et al. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014;14:159. doi:10.1186/1472-6882-14-159
Kellgren JH Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494-502. doi:10.1136/ard.16.4.494
Henrotin Y Labasse A Franck T Bosseloir A Bury T Deberg M. Collagen catabolism through Coll2-1 and Coll2-1NO2 and myeloperoxidase activity in marathon runners. Springerplus. 2013;2(1_suppl):92. doi:10.1186/2193-1801-2-92
Kong SY Stabler TV Criscione LG Elliott AL Jordan JM Kraus VB. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum. 2006;54(8):2496-504. doi:10.1002/art.21977
Karsdal MA Byrjalsen I Bay-Jensen AC Henriksen K Riis BJ Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis—the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord. 2010;11:125. doi:10.1186/1471-2474-11-125
Quintana DJ Garnero P Huebner JL Charni-Ben Tabassi N Kraus VB. PIIANP and HELIXII diurnal variation. Osteoarthritis Cartilage. 2008;16(10):1192-5. doi:10.1016/j.joca.2008.03.006
Gordon CD Stabler TV Kraus VB. Variation in osteoarthritis biomarkers from activity not food consumption. Clin Chim Acta. 2008;398(1-2):21-6. doi:10.1016/j.cca.2008.07.031
Bartels EM Christensen R Christensen P Henriksen M Bennett A Gudbergsen H, et al. Effect of a 16 weeks weight loss program on osteoarthritis biomarkers in obese patients with knee osteoarthritis: a prospective cohort study. Osteoarthritis Cartilage. 2014;22(11):1817-25. doi:10.1016/j.joca.2014.07.027
Jordan JM Luta G Stabler T Renner JB Dragomir AD Vilim V, et al. Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project. Arthritis Rheum. 2003;48(3):675-81. doi:10.1002/art.10822
Kraus VB Collins JE Hargrove D Losina E Nevitt M Katz JN, et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium. Ann Rheum Dis. 2017;76(1_suppl):186-95. doi:10.1136/annrheumdis-2016-209252
Mouritzen U Christgau S Lehmann HJ Tankó LB Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis. 2003;62(4):332-6. doi:10.1136/ard.62.4.332
Rousseau J-C Zhu Y Miossec P Vignon E Sandell LJ Garnero P, et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 2004;12(6):440-7. doi:10.1016/j.joca.2004.02.004
Verma P Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res. 2013;31(7):999-1006. doi:10.1002/jor.22324
